Novel structural hybrids of pyrazolobenzothiazines with benzimidazoles as cholinesterase inhibitors

European Journal of Medicinal Chemistry

Volumn 78, Issue , 2014, Pages 106-117

  Aslam, Sana ^a,b   Zaib, Sumera ^c   Ahmad, Matloob ^d   Gardiner, John M ^b   Ahmad, Aqeel ^b   Hameed, Abdul ^e   Furtmann, Norbert ^f   Gütschow, Michael ^f   Bajorath, Jürgen ^f   Iqbal, Jamshed ^c  

^a GOVERNMENT COLLEGE WOMEN UNIVERSITY   (Pakistan)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c Centre for Advanced Drug Research COMSATS Institute of Information Technology ^*  (Pakistan)

^d GOVERNMENT COLLEGE UNIVERSITY   (Pakistan)

^e UNIVERSITY OF KARACHI   (Pakistan)

^f UNIVERSITY OF BONN   (Germany)

Author keywords

Benzimidazole; Cholinesterases; Docking studies; Hybrid compounds; Pyrazolobenzothiazine

Indexed keywords

2 [4 (1,3 BENZOXAZOL 2 YL)PHENYL] 3,4 DIMETHYL 2,4 DIHYDROXYPYRAZOLO[4,3 C][1,2]BENZOTHIAZINE 5,5 DIOXIDE; 2 [4 (1H BENZIMIDAZOL 2 YL)PHENYL] 3,4 DIMETHYL 2,4 DIHYDROXYPYRAZOLO[4,3 C][1,2]BENZOTHIAZINE 5,5 DIOXIDE; 2 [4 (1H BENZIMIDAZOL 2 YL)PHENYL] 4 METHYL 3 PHENYL 2,4 DIHYDROXYPYRAZOLO[4,3 C][1,2]BENZOTHIAZINE 5,5 DIOXIDE; 2 [4 (4 METHYL 5,5 DIOXIDO 3 PHENYLBENZO[E]PYRAZOLO[4,3C][1,2]THIAZIN 2(4H) YL)PHENYL] 1H BENZO[D]IMIDAZOLE 5 CARBOXYLIC ACID; 2 [4 (5 BROMO 1H BENZIMIDAZOL 2 YL)PHENYL] 3,4 DIMETHYL 2,4 DIHYDROXYPYRAZOLO[4,3 C][1,2]BENZOTHIAZINE 5,5 DIOXIDE; 2 [4 (5 BROMO 1H BENZIMIDAZOL 2 YL)PHENYL] 4 METHYL 3 PHENYL 2,4 DIHYDROXYPYRAZOLO[4,3 C][1,2]BENZOTHIAZINE 5,5 DIOXIDE; 2 [4 (5 CARBOXY 1H BENZIMIDAZOL 2 YL)PHENYL] 3,4 DIMETHYL 2,4 DIHYDROXYPYRAZOLO[4,3 C][1,2]BENZOTHIAZINE 5,5 DIOXIDE; 2 [4 (5 CHLORO 1H BENZIMIDAZOL 2 YL)PHENYL] 3,4 DIMETHYL 2,4 DIHYDROXYPYRAZOLO[4,3 C][1,2]BENZOTHIAZINE 5,5 DIOXIDE; 2 [4 (5 CHLORO 1H BENZIMIDAZOL 2 YL)PHENYL] 4 METHYL 3 PHENYL 2,4 DIHYDROXYPYRAZOLO[4,3 C][1,2]BENZOTHIAZINE 5,5 DIOXIDE; 2 [4 (5 METHOXY 1H BENZIMIDAZOL 2 YL)PHENYL] 3,4 DIMETHYL 2,4 DIHYDROXYPYRAZOLO[4,3 C][1,2]BENZOTHIAZINE 5,5 DIOXIDE; 2 [4 (5 METHYL 1H BENZIMIDAZOL 2 YL)PHENYL] 3,4 DIMETHYL 2,4 DIHYDROXYPYRAZOLO[4,3 C][1,2]BENZOTHIAZINE 5,5 DIOXIDE; 2 [4 (5 METHYL 1H BENZIMIDAZOL 2 YL)PHENYL] 4 METHYL 3 PHENYL 2,4 DIHYDROXYPYRAZOLO[4,3 C][1,2]BENZOTHIAZINE 5,5 DIOXIDE; 2 [4 (5 NITRO 1H BENZIMIDAZOL 2 YL)PHENYL] 3,4 DIMETHYL 2,4 DIHYDROXYPYRAZOLO[4,3 C][1,2]BENZOTHIAZINE 5,5 DIOXIDE; 2 [4 (5,6 DIMETHYL 1H BENZIMIDAZOL 2 YL)PHENYL] 3,4 DIMETHYL 2,4 DIHYDROXYPYRAZOLO[4,3 C][1,2]BENZOTHIAZINE 5,5 DIOXIDE; 3 ACETYL 4 HYDROXY 2 METHYL 2H 1,2 BENZOTHIAZINE 1,1 DIOXIDE; 3 BENZOYL 4 HYDROXY 2 METHYL 2H 1,2 BENZOTHIAZINE 1,1 DIOXIDE; 3,4 DIMETHYL 2 [4 (9H PURIN 8 YL)PHENYL] 2,4 DIHYDROXYPYRAZOLO[4,3 C][1,2]BENZOTHIAZINE 5,5 DIOXIDE; 3,4 DIMETHYL 2,4 DIHYDROPYRAZOLO[4,3 C][1,2]BENZOTHIAZINE 5,5 DIOXIDE; 4 (3,4 DIMETHYL 5,5 DIOXIDOBENZO[E]PYRAZOLO[4,3 C][1,2]THIAZIN 2(4H) YL)BENZALDEHYDE; 4 (4 METHYL 5,5 DIOXIDO 3 APHENYLBENZO[E]PYRAZOLO[4,3 C][1,2]THIAZIN 2(4H) YL)BENZALDEHYDE; 4 METHYL 3 PHENYL 2,4 DIHYDROBENZO[E]PYRAZOLO[4,3 C][1,2]BENZOTHIAZINE 5,5 DIOXIDE; ACETYLCHOLINESTERASE; BENZIMIDAZOLE DERIVATIVE; BENZOTHIADIAZINE DERIVATIVE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DIAMINE DERIVATIVE; ETHYL 2 [4 (3,4 DIMETHYL 5,5 DIOXIDOBENZO[E]PYRAZOLOL[4,3 C][1,2]THIAZIN 2(4H) YL)PHENYL] 1H BENZO[D]IMIDAZOLE 5 CARBOXYLATE; SACCHARIN SODIUM; UNCLASSIFIED DRUG; UNINDEXED DRUG; PYRAZOLE DERIVATIVE; THIAZINE DERIVATIVE;

ARTICLE; ARYLATION; DRUG POTENCY; DRUG SYNTHESIS; ENZYME INHIBITION; HYBRID; IC 50; MOLECULAR DOCKING; STRUCTURE ACTIVITY RELATION; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; METABOLISM; SYNTHESIS;

ACETYLCHOLINESTERASE; BENZIMIDAZOLES; BUTYRYLCHOLINESTERASE; CHOLINESTERASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PYRAZOLES; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZINES;

EID: 84897071497     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2014.03.035     Document Type: Article

References (44)

1. E. Giacobini International Journal of Geriatric Psychiatry 18 2003 S1 S5
2. C. Geula, and M.M. Mesulam Alzheimer Disease and Associated Disorders 9 Suppl. 2 1995 23 28
3. D.K. Lahiri, M.R. Farlow, K. Sambamurti, N.H. Greig, E. Giacobini, and L.S. Schneider Current Drug Targets 4 2003 97 112
4. H. Soreq, and S. Seidman Nature Reviews Neuroscience 2 2001 294 302
5. N.H. Greig, T. Utsuki, Q. Yu, X. Zhu, H.W. Holloway, T. Perry, B. Lee, D.K. Ingram, and D.K. Lahiri Current Medical Research and Opinion 17 2001 159 165
6. D.H. Small, and C.A. McLean Journal of Neurochemsitry 73 1999 443 449
7. D.H. Small, S.S. Mok, and J.C. Bornstein Nature Reviews Neuroscience 2 2001 595 598
8. M. Mesulam, A. Guillozet, P. Shaw, and B. Quinn Neurobiology of Disease 9 2002 88 93
9. S. Darvesh, D.L. Grantham, and D.A. Hopkins Journal of Comparative Neurology 393 1998 374 390
10. S. Darvesh, D.A. Hopkins, and C. Geula Nature Reviews Neuroscience 4 2003 131 138
11. U. Neumann, and M. Gütschow Bioorganic Chemistry 23 1995 72 88
12. A. Stößel, M. Schlenk, S. Hinz, P. Küppers, J. Heer, M. Gütschow, and C.E. Müller Journal of Medicinal Chemistry 56 2013 4580 4596
13. G. Manina, M.R. Pasca, S. Buroni, E. De Rossi, and G. Riccardi Current Medicinal Chemistry 17 2010 3099 3108
14. R.R. Gupta, P.K. Dev, M.L. Sharma, C.M. Rajoria, A. Gupta, and M. Nyati Anticancer Drugs 4 1993 589 592
15. S. Sabatini, G.W. Kaatz, G.M. Rossolini, D. Brandini, and A. Fravolini Journal of Medicinal Chemistry 51 2008 4321 4330
16. A. Martelli, G. Manfroni, P. Sabbatini, M.L. Barreca, L. Testai, M. Novelli, S. Sabatini, S. Massari, O. Tabarrini, P. Masiello, V. Calderone, and V. Cecchetti Journal of Medicinal Chemistry 56 2013 4718 4728
17. M. Ahmad, S.U.F. Rizvi, H.L. Siddiqui, S. Ahmad, M. Parvez, and R. Suliman Medicinal Chemistry Research 21 2012 2340 2348
18. J. Wang, D. Limburg, J. Carter, G. Mbalaviele, J. Gierse, and M. Vazquez Bioorganic & Medicinal Chemistry Letters 20 2010 1604 1609
19. M. Zia-ur-Rehman, J.A. Choudary, S. Ahmad, and H.L. Siddiqui Chemical and Pharmaceutical Bulletin 54 2006 1175 1178
20. P.K. Sharma, and S.N. Sawhney Bulletin of the Chemical Society of Japan 66 1993 3843 3846
21. M.L. Barreca, G. Manfroni, P. Leyssen, J. Winquist, N. Kaushik-Basu, J. Paeshuyse, R. Krishnan, N. Iraci, S. Sabatini, O. Tabarrini, A. Basu, U.H. Danielson, J. Nevts, and V. Cecchetti Journal of Medicinal Chemistry 56 2013 2270 2282
22. N. Tomita, Y. Hayashi, S. Suzuki, Y. Oomori, Y. Aramaki, Y. Matsushita, M. Iwatani, H. Iwata, A. Okabe, Y. Awazu, O. Isono, R.J. Skene, D.J. Hosfield, H. Miki, T. Kawamoto, A. Hori, and A. Baba Bioorganic & Medicinal Chemistry Letters 23 2013 1779 1785
23. A. Barazarte, G. Lobo, N. Gamboa, J.R. Rodrigues, M.V. Capparelli, A. Alvarez-Larena, S.E. Lopez, and J.E. Charris European Journal of Medicinal Chemistry 44 2009 1303 1310
24. M. Ahmad, H.L. Siddiqui, J.M. Gardiner, M. Parvez, and S. Aslam Medicinal Chemistry Research 22 2013 794 805
25. M. Ahmad, H.L. Siddiqui, M. Zia-ur-Rehman, and M. Parvez European Journal of Medicinal Chemistry 45 2010 698 704
26. A.R. Porcari, R.V. Devivar, L.S. Kucera, J.C. Drach, and L.B. Townsend Journal of Medicinal Chemistry 41 1998 1252 1262
27. T. Roth, M.L. Morningstar, P.L. Boyer, S.H. Hughes, R.W. Buckheit, and C.J. Michejda Journal of Medicinal Chemistry 40 1997 4199 4207
28. M.T. Migawa, J.-L. Girardet, J.A. Walker, G.W. Koszalka, S.D. Chamberlain, J.C. Drach, and L.B. Townsend Journal of Medicinal Chemistry 41 1998 1242 1251
29. S.R. LaPlante, A. Jakalian, N. Aubry, Y. Bousquet, J.M. Ferland, J. Gillard, S. Lefebvre, M. Poirier, Y.S. Tsantrizos, G. Kukolj, and P.L. Beaulieu Angewandte Chemie International Edition 43 2004 4306 4311
30. W.A. Denny, G.W. Rewcastle, and B.C. Baguley Journal of Medicinal Chemistry 33 1990 814 819
31. J.S. Kim, B. Gatto, C. Yu, A. Liu, L.F. Liu, and E.J. LaVoie Journal of Medicinal Chemistry 39 1996 992 998
32. J. Valdez, R. Cedillo, A. Hernandez-Campos, L. Yepez, F. Hernandez-Luis, G. Navarrete-Vazquez, A. Tapia, R. Cortes, M. Hernandez, and R. Castillo Bioorganic & Medicinal Chemistry Letters 12 2002 2221 2224
33. Y. Kohara, K. Kubo, E. Imamiya, T. Wada, Y. Inada, and T. Naka Journal of Medicinal Chemistry 39 1996 5228 5235
34. T. Fekner, J. Gallucci, and M.K. Chan Journal of the American Chemical Society 126 2004 223 236
35. P.W. Elsinghorst, W. Härtig, D. Gündisch, K. Mohr, C. Tränkle, and M. Gütschow Current Topics in Medicinal Chemistry 11 2011 2731 2748
36. C. Galdeano, E. Viayna, P. Arroyo, A. Bidon-Chanal, J.R. Blas, D. Muñoz-Torrero, and F.J. Luque Current Pharmaceutical Design 16 2010 2818 2836
37. P.W. Elsinghorst, W. Härtig, S. Goldhammer, J. Grosche, and M. Gütschow Organic & Biomolecular Chemistry 7 2009 3940 3946
38. M. Ahmad, H.L. Siddiqui, M. Azam, I.H. Bukhari, and M. Parvez Acta Crystallographica E66 2010 o616
39. M. Ahmad, H.L. Siddiqui, U.F. Rizvi, S. Ahmad, and M. Parvez Acta Crystallographica E66 2010 o862
40. G.L. Ellman, K.D. Courtney, V. Andres Jr., and R.M. Feather-Stone Biochemical Pharmacology 7 1961 88 95
41. F. Nachon, E. Carletti, C. Ronco, M. Trovaslet, Y. Nicolet, L. Jean, and P.Y. Renard Biochemical Journal 453 2013 393 399
42. P.W. Rose, C. Bi, W.F. Bluhm, C.H. Christie, D. Dimitropoulos, S. Dutta, R.K. Green, D.S. Goodsell, A. Prlic, M. Quesada, G.B. Quinn, A.G. Ramos, J.D. Westbrook, J. Young, C. Zardecki, H.M. Berman, and P.E. Bourne Nucleic Acids Research 41 2013 D475 D482
43. G.M. Morris, R. Huey, W. Lindstrom, M.F. Sanner, R.K. Belew, D.S. Goodsell, and A.J. Olson Journal of Computational Chemistry 30 2009 2785 2791
44. Molecular Operating Environment (MOE), (2012).10; Chemical Computing Group Inc., Montreal, Canada.